CUSIP 45719W205COM NEWIKTQ4 2025
21 filings · latest Feb 17, 2026
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Sands Capital Alternatives, LLC | 13.02M | $26.69M |
| 2 | Soleus Capital Management, L.P. | 10.88M | $22.29M |
| 3 | Fairmount Funds Management LLC | 8.63M | $17.68M |
| 4 | Adar1 Capital Management, LLC | 8.06M | $16.53M |
| 5 | Trails Edge Capital Partners, LP | 6.18M | $12.67M |
| 6 | Blackstone Inc. | 5.94M | $12.17M |
| 7 | Siren, L.L.C. | 5.85M | $11.99M |
| 8 | Perceptive Advisors LLC | 5.42M | $11.11M |
| 9 |
| 4 | Feb 13, 2026 | Sands Capital Life Sciences Pulse Fund II, L.P. | 13G/A | 10.8% | 13.02M | SEC |
| 5 | Feb 13, 2026 | Nantahala Capital Management, LLC | 13G/A | 5.7% | 7.04M | SEC |
| 6 | Dec 31, 2025 | Trails Edge Capital Partners, LP | 13G | 5.1% | 6.15M | SEC |
| 7 | Aug 14, 2025 | Adar1 Capital Management, LLC | 13G/A | 13.0% | 7.74M | SEC |
| 8 | Aug 13, 2025 | Sands Capital Life Sciences Pulse Fund II, L.P. | 13G/A | 14.7% | 10.95M | SEC |
| 9 | Feb 14, 2025 | Armistice Capital, LLC | 13G/A | 5.0% | 3.53M | SEC |
| 10 | Feb 14, 2025 | Adar1 Capital Management, LLC | 13G | 13.0% | 6.99M | SEC |
See the full Schedule 13D/13G history for Inhibikase Therapeutics Inc.
Unlock full history| Commodore Capital LP |
| 5.40M |
| $11.06M |
| 10 | Vanguard Group Inc | 4.56M | $9.35M |